Relapse or no relapse in multiple sclerosis: Can disease activity biomarkers support the clinician?

ABSTRACT:

Background

In relapsing-remitting multiple sclerosis (RRMS), the assessment of clinical disease activity can be challenging.

Objectives

To determine the diagnostic potential of serum neurofilament light (sNfL) and glial fibrillary acidic protein (sGFAP) to distinguish a relapse from other causes of deterioration.

Methods

In this multicenter, prospective study, RRMS patients with new neurological symptoms in the last 14 days were followed for 12 weeks. A diagnosis was established by the treating physician or, when in doubt, a panel of experienced neurologists. Blood samples were taken at baseline and week 12.

Results

A total of 65 patients were included. At baseline, patients with a clear relapse had a significantly higher median sNfL (14.6 pg/mL) than those wit

SUBMITTER: van Pamelen J 

PROVIDER: S-EPMC12405697 | biostudies-literature | 2025 Jul-Sep

REPOSITORIES: biostudies-literature